| 10x Genomics is a life science technology company. Co.'s integrated platform solutions include instruments, consumables and software. Co.'s commercial product portfolio utilizes its Chromium X Series and Chromium Connect, its Visium CytAssist, an instrument designed to simplify the Visium solution workflow, its Xenium Analyzer, an instrument designed for high-throughput analysis of cells in their tissue environment, and its proprietary microfluidic chips, slides, reagents and other consumables for its Chromium, Visium and Xenium solutions. Co. bundles its software with these products to guide customers through the workflow, from sample preparation through analysis and visualization. The TXG average annual return since 2019 is shown above.
The Average Annual Return on the TXG average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether TXG average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the TXG average annual return calculation with any dividends reinvested as applicable (on ex-dates).